Race Oncology Limited
ASX:RAC 株式レポート
Race Oncology マネジメント Race Oncologyの CEO はDaniel Tillettで、 Nov2023年に任命され、 の在任期間は 1 年未満です。 の年間総報酬はA$ 1.12Mで、 13%給与と87%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の10.13%を直接所有しており、その価値はA$ 25.38M 。経営陣と取締役会の平均在任期間はそれぞれ0.9年と2年です。
主要情報 CEO給与比率 13.0% CEO在任期間 less than a year CEOの所有権 10.1% 経営陣の平均在職期間 less than a year 取締役会の平均在任期間 2yrs
経営陣の近況
Race Oncology Limited, Annual General Meeting, Nov 25, 2024 Oct 07
Race Oncology Limited Appoints Daniel Tillett as Chief Executive Officer Nov 22
Race Oncology Limited, Annual General Meeting, Nov 27, 2023 Oct 10
Race Oncology Limited Announces Board Changes Aug 22
Race Oncology Limited Announces Board Changes Jun 29
Race Oncology Limited Appoints Michelle Rashford Chief Medical Officer, Effective 1 July 2023 May 09
すべての更新を表示
Race Oncology Limited, Annual General Meeting, Nov 25, 2024 Oct 07
Consensus revenue estimates increase by 12% Oct 01
Is Race Oncology (ASX:RAC) In A Good Position To Deliver On Growth Plans? Aug 26
Price target increased by 26% to AU$3.22 Jun 29
New minor risk - Share price stability Jun 06
New minor risk - Shareholder dilution May 17
We Think Race Oncology (ASX:RAC) Needs To Drive Business Growth Carefully May 10
New minor risk - Shareholder dilution Mar 30
New major risk - Financial position Feb 29
We're Not Very Worried About Race Oncology's (ASX:RAC) Cash Burn Rate Jan 23
Race Oncology Limited Appoints Daniel Tillett as Chief Executive Officer Nov 22
Race Oncology Limited, Annual General Meeting, Nov 27, 2023 Oct 10
Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation Oct 05
New minor risk - Share price stability Oct 05
New minor risk - Financial data availability Aug 30
Race Oncology Limited Announces Board Changes Aug 22
New minor risk - Market cap size Aug 15
Race Oncology Limited Announces Board Changes Jun 29
Companies Like Race Oncology (ASX:RAC) Are In A Position To Invest In Growth Jun 20
Race Oncology Limited Appoints Michelle Rashford Chief Medical Officer, Effective 1 July 2023 May 09
We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow Feb 17
Race Oncology Limited Appoints Damian Clarke-Bruce as Director Feb 02
Race Oncology Limited Receives Human Ethics Approval for Observational Cardioprotection Breast Cancer Trial Feb 01
Race Oncology Limited, Annual General Meeting, Feb 21, 2023 Jan 19
Board Member recently bought AU$50k worth of stock Jan 17
Board Member recently bought AU$99k worth of stock Dec 23 Race Oncology Limited Appoints Damian Clarke-Bruce as Managing Director, Effective 1 February 2023
Race Oncology Limited Announces It Has Submitted A Human Ethics Application to Hunter New England Human Research Ethics Committee Seeking Approval to Commence the Observational Stage of A Planned Phase 1/2B Clinical Trial of Zantrene Dec 10
Race Oncology Limited Appoints Daniel (Danny) Sharp as an Independent Non-Executive Director Dec 05
Race Oncology Limited Receives Positive Guidance on Zantrene Via Pre-IND Meeting with US FDA Nov 23
High number of new and inexperienced directors Nov 16
Race Oncology Ltd Announces Management Changes Nov 11
Here's Why We're Not At All Concerned With Race Oncology's (ASX:RAC) Cash Burn Situation Oct 14
Race Oncology Limited, Annual General Meeting, Nov 24, 2022 Oct 04
Race Oncology Limited Develops Improved Iv Formulation of Zantrene Sep 28
Race Oncology Limited Initiates New Drug Discovery Program Sep 27
Board Member recently bought AU$165k worth of stock Sep 27
Race Oncology Limited Shares Further Interim Results from Preclinical Cardioprotection Program in Collaboration with Researchers from the University of Newcastle Jun 30
Race Oncology Limited Announces Interim Results from its Preclinical Melanoma Research Program Jun 22
Race Oncology Limited Expands FTO Targeting Phase 1b/2a Extramedullary AML & MDS Trial to Europe Jun 09
Race Oncology Limited Announces the Dose Escalation Phase 1b Stage of the Relapsed or Refractory Acute Myeloid Leukaemia (R/R AML) Trial Running At the Chaim Sheba Medical Centre, Israel May 27
Race Oncology Limited Appoints Guy Breitenbucher to Its Scientific Advisory Board May 19
Race Oncology Limited Receives Governance Approval for AML EMD & MDS Trial May 12
High number of new and inexperienced directors Apr 27
Race Oncology Limited Receives Human Ethics Approval for Its Open Label Clinical Trial of Zantrene in Patients with Extramedullary Acute Myeloid Leukaemia or High-Risk Myelodysplastic Syndrome Apr 06
Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation Apr 01
Race Oncology Limited Announces Preclinical & Clinical Programs Update Mar 31
Board Member recently bought AU$56k worth of stock Mar 06
Race Oncology Limited Announces MD Anderson Cancer Center Collaborators Publish Peer Reviewed AML Preclinical Study on Zantrene Feb 24
Race Oncology Limited Appoints Christina Manfre as Chief Financial Officer Jan 31
Non-Independent Non-Executive Chairman recently sold AU$995k worth of stock Jan 11
Board Member recently bought AU$59k worth of stock Dec 17
Insider recently sold AU$4.4m worth of stock Nov 30
Race Oncology Limited Announces Interim Results from the Zantrene® Preclinical Heart Safety Research Program Led by Eminent Cardiotoxicity Researchers, Associate Professors Aaron Sverdlov and Doan Ngo Nov 22
Non-Independent Non-Executive Chairman exercised options to buy AU$9.8m worth of stock. Nov 14
Non-Independent Non-Executive Chairman recently bought AU$710k worth of stock Nov 08
Non-Executive Chairman recently sold AU$193k worth of stock Sep 07
Non-Executive Chairman exercised options to buy AU$5.7m worth of stock. Aug 25
Insider recently sold AU$4.3m worth of stock Aug 04
Race Oncology Limited Executes Contract to Commence Phase 1b/2 AML Trial at Chaim Sheba Israel Jun 23
Insider recently sold AU$4.8m worth of stock Apr 27
We're Hopeful That Race Oncology (ASX:RAC) Will Use Its Cash Wisely Apr 05
Insider recently sold AU$6.6m worth of stock Mar 16
Race Oncology Limited Announces Compelling Preclinical Breast Cancer Results Mar 10
Insider recently sold AU$2.1m worth of stock Mar 08
What Percentage Of Race Oncology Limited (ASX:RAC) Shares Do Insiders Own? Mar 01
New 90-day high: AU$3.29 Feb 25
Race Oncology Limited Announces Positive Early Preclinical Ovarian Cancer Results Feb 23
Professor Borje Andersson to Resign as Chief Medical Officer of Race Oncology Limited Feb 19
Race Oncology Limited Appoints Mary Harney as Non-Executive Director Feb 08
New 90-day high: AU$2.48 Feb 05
How Much Are Race Oncology Limited (ASX:RAC) Insiders Taking Off The Table? Jan 07
Race Oncology Limited Announces Borje Andersson Resigns as an Executive Director Dec 10
Race Oncology Limited Announces Breast Cancer Clinical Trial Program Initiated Nov 27
New 90-day high: AU$1.30 Nov 09
Race Oncology Limited Reports Phase II Bisantrene Trial Data to be presented at ASH 2020 Nov 06
Race Oncology Limited Announces Director Resignations Oct 29
New 90-day low: AU$0.76 Oct 06
Race Oncology Limited Appoints Borje S. Andersson as Chief Medical Officer and Executive Director Oct 02
Race Oncology Limited Appoints Phil Lynch as Chief Executive Officer Sep 03 Race Oncology Limited announced that it expects to receive AUD 3 million in funding from Merchant Funds Management Pty Ltd and other investors
CEO報酬分析 Race Oncology の収益と比較して、Daniel Tillett の報酬はどのように変化したか？ 日付 総報酬 給与 会社業績 Jun 30 2024 AU$1m AU$145k -AU$14m
Mar 31 2024 n/a n/a -AU$12m
Dec 31 2023 n/a n/a -AU$11m
Sep 30 2023 n/a n/a -AU$11m
Jun 30 2023 AU$836k AU$332k -AU$10m
Mar 31 2023 n/a n/a -AU$10m
Dec 31 2022 n/a n/a -AU$11m
Sep 30 2022 n/a n/a -AU$11m
Jun 30 2022 AU$1m AU$228k -AU$11m
Mar 31 2022 n/a n/a -AU$10m
Dec 31 2021 n/a n/a -AU$9m
Sep 30 2021 n/a n/a -AU$8m
Jun 30 2021 AU$1m AU$167k -AU$6m
Mar 31 2021 n/a n/a -AU$5m
Dec 31 2020 n/a n/a -AU$4m
Sep 30 2020 n/a n/a -AU$4m
Jun 30 2020 AU$147k n/a -AU$4m
報酬と市場: Danielの 総報酬 ($USD 731.73K ) は、 Australian市場 ($USD 668.22K ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Danielの報酬は増加しましたが、会社は利益を上げていません。
CEO（最高経営責任者 Dr. Daniel Tillett is Non-Executive Director of Tryptamine Therapeutics Limited from November 8, 2024. Dr. Tillett joined the Tryptamine Therapeutics Limited on November 8, 2024. Dr. Tillett has been Chief ... Show more
リーダーシップ・チーム 名称 ポジション 在職期間 報酬 所有権 Executive Chairman 1.4yrs AU$327.72k データなし CEO, Managing Director & Director less than a year AU$1.12m 10.13% A$ 25.4m Chief Medical Officer 1.3yrs AU$704.81k データなし Chief Financial Officer less than a year データなし データなし Vice President of Operations & Strategy less than a year データなし データなし Company Secretary 8.5yrs データなし データなし
もっと見る
経験豊富な経営陣: RACの経営陣は 経験豊富 とはみなされません ( 0.9年の平均在職年数)。これは新しいチームを示唆しています。
取締役 名称 ポジション 在職期間 報酬 所有権 Executive Chairman 1.4yrs AU$327.72k データなし CEO, Managing Director & Director less than a year AU$1.12m 10.13% A$ 25.4m Member of Scientific Advisory Board 7.9yrs データなし データなし Member of Scientific Advisory Board no data データなし データなし Member of Scientific Advisory Board no data データなし データなし Chairman of Clinical Advisory Board 4.9yrs AU$815.36k データなし Member of Clinical Advisory Board 4.8yrs データなし データなし Member of Scientific Advisory Board 3.6yrs データなし データなし Member of Scientific Advisory Board 2.5yrs データなし データなし Clinical Advisory Board less than a year データなし データなし Member of Scientific Advisory Board less than a year データなし データなし Independent Non-Executive Director less than a year データなし データなし
もっと見る
経験豊富なボード: RACの 取締役会 は 経験豊富 ではない ( 2年の平均在任期間) ため、新しい取締役会が必要であると考えられます。
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
